| PMGC Holdings Inc. Announces Filing of Quarterly Report on Form 10-Q |
NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”) today announced that it has filed its Quarterly Report on Form 10-Q (“Quarterly Report”) for the three months ended March 31, 2025, with the U.S. Securities and Exchange Commission (“SEC”). |
globenewswire.com |
2025-05-14 20:30:00 |
Czytaj oryginał (ang.) |
| PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT) |
NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital,” “we,” “our,” or “us”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission disclosing beneficial ownership of common stock in Alaunos Therapeutics, Inc. (Nasdaq: TCRT). |
globenewswire.com |
2025-05-14 12:00:00 |
Czytaj oryginał (ang.) |
| RESEND - Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health |
NEWPORT BEACH, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced the filing of four novel patent applications for its two candidates EL-22 and EL-32. |
globenewswire.com |
2025-04-29 16:15:00 |
Czytaj oryginał (ang.) |
| Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Phase 2 Clinical Trial |
Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Pha |
globenewswire.com |
2025-04-28 12:00:00 |
Czytaj oryginał (ang.) |
| PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Custom IT Packaging Company |
NEWPORT BEACH, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: PMGC) (the “Company,” “PMGC,” “we,” or “us”), a diversified public holding company, is pleased to announce the signing of a non-binding Letter of Intent (“LOI”) to acquire a U.S.-based, cash-flow positive information technology (“IT”) custom packaging company. |
globenewswire.com |
2025-04-16 12:00:00 |
Czytaj oryginał (ang.) |
| Nestpoint Group Fuels Univest Securities, LLC's Ascent to Investment Banking Powerhouse in Trump's Economic Golden Age |
New York, New York, April 07, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), New York's premier boutique investment bank, is proud to announce a strategic investment from Nestpoint Group (“Nestpoint”), a leading firm in government affairs, finance, and private equity based in Dallas and Washington, D.C. This powerhouse partnership positions Univest to rise as a global investment banking leader, harnessing unparalleled opportunities for economic expansion under the Trump administration's bold vision for American prosperity. |
globenewswire.com |
2025-04-07 21:30:00 |
Czytaj oryginał (ang.) |
| PMGC Holdings Inc. Announces Filing of Annual Report on Form 10-K |
NEWPORT BEACH, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”) today announced that it has filed its Annual Report on Form 10-K (“Annual Report”) for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (“SEC”). |
globenewswire.com |
2025-03-28 10:00:00 |
Czytaj oryginał (ang.) |
| NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market |
The U.S. animal health market was valued at USD 12.65 billion in 2024 and is expected to grow at a CAGR of 7.97% from 2025 to 2030. This growth is believed to be a consequence of rising innovations surrounding companion animal pharmaceuticals, increasing millennial pet adoption rates, growing livestock populations and production in developing countries, and increasing meat or milk consumption rates, coupled with rising concerns about food-borne diseases. |
globenewswire.com |
2025-03-27 10:00:00 |
Czytaj oryginał (ang.) |
| Univest Securities, LLC Announces Closing of $1.48 Million Registered Direct Offering for its Client PMGC Holdings Inc. (NASDAQ: ELAB) |
New York, New York, March 24, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered direct offering (the “Offering”) for its client PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company”), a diversified holding company. |
globenewswire.com |
2025-03-24 19:00:00 |
Czytaj oryginał (ang.) |
| PMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules |
NEWPORT BEACH, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”), a diversified holding company, today announced that it has entered into a definitive agreement with several investors for the purchase and sale of an aggregate of 294,450 of the Company's common stock, par value $0.0001 per share (the “Shares”) (or pre-funded warrants in lieu thereof) at a purchase price of $5.04 per share in a registered direct offering priced at-the-market under Nasdaq. |
globenewswire.com |
2025-03-21 16:41:00 |
Czytaj oryginał (ang.) |
| PMGC Holdings Announces Share Repurchases from Existing Shareholders |
NEWPORT BEACH, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”) today announced that it has repurchased shares from certain existing shareholders who contacted the Company directly. |
globenewswire.com |
2025-03-21 10:00:00 |
Czytaj oryginał (ang.) |
| PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group |
NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company” or “PMGC,” “our,” or “we”) (Nasdaq: ELAB), a diversified holding company, is proud to announce its annual sponsorship of TCA Venture Group's (“TCA”) Orange County network for 2025. |
globenewswire.com |
2025-02-27 10:00:00 |
Czytaj oryginał (ang.) |
| PMGC Holdings Highlights Strong Capital Position: No Debt, Fully Funded, and Warrants Priced Above Market |
NEWPORT BEACH, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company,” “PMGC,” “us,” or “we”) (Nasdaq:ELAB), a diversified holding company, today announced an update on its capital structure, highlighting its financial position and ongoing commitment to executing its strategic priorities through its operating subsidiaries. |
globenewswire.com |
2025-02-26 10:30:00 |
Czytaj oryginał (ang.) |
| Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1 |
Northstrive Biosciences, a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservatio |
globenewswire.com |
2025-02-04 10:00:00 |
Czytaj oryginał (ang.) |
| PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fire Prevention Technology Companies |
PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fir |
globenewswire.com |
2025-01-31 12:33:00 |
Czytaj oryginał (ang.) |
| Univest Securities, LLC Announces Closing of $1.92 Million Warrant Inducement for its Client PMGC Holdings Inc. (NASDAQ: ELAB) |
New York, New York, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the completion of the previously announced warrant inducement with existing institutional investors for its client PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB), a diversified holding company, for the exercise of certain outstanding Series A warrants that the Company issued on September 24, 2024. |
globenewswire.com |
2025-01-28 19:00:00 |
Czytaj oryginał (ang.) |
| PMGC Holdings Inc. Announces $1.9 Million in Gross Proceeds from Warrant Inducement with Institutional Investors |
NEWPORT BEACH, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) a diversified holding company today announced it has entered into a warrant inducement agreement with existing institutional investors for the exercise of certain outstanding Series A warrants that the Company issued on September 24, 2024. |
globenewswire.com |
2025-01-27 11:00:00 |
Czytaj oryginał (ang.) |
| Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium |
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium |
globenewswire.com |
2025-01-24 10:00:00 |
Czytaj oryginał (ang.) |
| PMGC Holdings Inc. Announces Closing of Elevai Skincare Divestiture |
NEWPORT BEACH, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) a diversified holding company today announced the closing of the previously announced divestiture of its 100% wholly owned subsidiary Elevai Skincare Inc. (“Elevai”) pursuant to a definitive purchase agreement with Carmell Corporation (“Carmell”) (the “Divestiture”) and reaffirms its commitment to accelerating shareholder value creation and market leadership following the sale of its skincare subsidiary, Elevai Skincare. |
globenewswire.com |
2025-01-16 10:31:00 |
Czytaj oryginał (ang.) |
| PMGC Holdings Inc. Announces Name Change of Wholly Owned Subsidiaries |
PMGC Research Inc., formerly Elevai Research Inc., is a development company focused on public-private collaborations leveraging research grants. Northstrive Biosciences Inc., formerly Elevai Biosciences, Inc., is a biopharmaceutical company targeting obesity with next-generation treatments. |
globenewswire.com |
2025-01-15 11:30:00 |
Czytaj oryginał (ang.) |
| PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy |
Divestiture Highlights Strategic Plans on Potential High-Impact Acquisitions Strategic Divestment Reduces Cash Burn and Enhances Operational Efficiency NEWPORT BEACH, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) today announced its commitment to accelerating shareholder value creation and market leadership following the sale of its skincare subsidiary, Elevai Skincare. |
globenewswire.com |
2025-01-02 17:55:00 |
Czytaj oryginał (ang.) |
| Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products |
Carmell and PMGC Holdings Inc Announce Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair |
globenewswire.com |
2025-01-02 10:00:00 |
Czytaj oryginał (ang.) |
| Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada |
NEWPORT BEACH, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (Nasdaq: ELAB) (before and after the redomestication, the “Company” or “we”) announced today that it completed a strategic reorganization. |
globenewswire.com |
2024-12-20 21:30:00 |
Czytaj oryginał (ang.) |
| Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada |
NEWPORT BEACH, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (Nasdaq: ELAB) (before and after the redomestication, the “Company” or “we”) announced today that it plans to effectuate a strategic reorganization effective on December 20, 2024. This reorganization will include changing the Company's name from Elevai Labs Inc. to PMGC Holdings Inc. and redomiciling from Delaware to Nevada. After this reorganization, the Company will continue to trade on The Nasdaq Stock Market (“Nasdaq”) under the ticker symbol “ELAB.” The redomestication and name change will be effective on Nasdaq at the opening of business on December 23, 2024. |
globenewswire.com |
2024-12-20 09:30:00 |
Czytaj oryginał (ang.) |
| Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market |
Elevai Skincare Expands into Hair Care with Cutting-Edge Scalp and Hair Health System. Root Renewal System Features Exclusive Technologies and Science-Driven Formulations. |
globenewswire.com |
2024-12-06 09:30:00 |
Czytaj oryginał (ang.) |
| Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance |
NEWPORT BEACH, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (Elevai" or the "Company") announced today it will implement a 1-for-200 reverse stock split (“Reverse Stock Split”) of its common stock, which will be effective at midnight on November 27, 2024. |
globenewswire.com |
2024-11-22 20:23:00 |
Czytaj oryginał (ang.) |
| Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess |
NEWPORT BEACH, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a leader in medical aesthetics, announced today that it is has withdrawn the previously announced offer (the “Offer”) to holders of the Company's outstanding Common Stock (the “Common Stock”), to exchange up to 15,000,000 shares of Common Stock for up to 15,000,000 shares of the Company's newly issued Series B Preferred Stock (“Series B Preferred Stock”), as a result of notice from the Depositary Trust Company (“DTC”) that due to logistical issues, DTC would not be able to accept the tenders of Common Stock. |
globenewswire.com |
2024-11-22 19:00:00 |
Czytaj oryginał (ang.) |
| CORRECTION - Elevai Labs Inc. |
NEWPORT BEACH, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- In a release earlier today by Elevai Labs Inc. (NASDAQ: ELAB), please note that in the headline and first paragraph, the financial results are from the company's third fiscal quarter of 2024, not the second fiscal quarter as previously stated; as such, the header over the first bullet list should note the financial results as being from the three and nine months ended September 30, 2024, rather than the three and six months ended June 30, 2024 as previous stated. |
globenewswire.com |
2024-11-14 16:35:00 |
Czytaj oryginał (ang.) |
| Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update |
Achieves Robust Financial Performance with 74% Gross Margin and Strategic Public Offering, Bolstering Resources for Continued Growth and Innovation. Elevai Enfinity™ Clinical Trials Showcase Breakthroughs in Skin Firmness, Tone, and Wrinkle Reduction, Reinforcing Leadership in Aesthetic Innovation. |
globenewswire.com |
2024-11-14 11:08:00 |
Czytaj oryginał (ang.) |
| Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange |
NEWPORT BEACH, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a leader in medical aesthetics, announced today that it is has amended and restated the Offer to Exchange, including extending the expiration date, of its previously announced offer (the “Offer”) to holders of the Company's outstanding Common Stock (the “Common Stock”), to exchange up to 15,000,000 shares of Common Stock for up to 15,000,000 shares of the Company's newly issued Series B Preferred Stock (“Series B Preferred Stock”), with each share of Common Stock being exchangeable in for one share of Series B Preferred Stock. |
globenewswire.com |
2024-11-04 19:45:00 |
Czytaj oryginał (ang.) |
| Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity |
NEWPORT BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- EL-22 is a novel myostatin asset for the potential treatment of obesity in combination with existing GLP-1 medicines The Investigational New Drug application is planned for submission to the U.S. Food and Drug Administration (“FDA”) in 2025 Muscle wasting is a common side effect of popular GLP-1 weight-loss medications, with no current approved treatments. |
globenewswire.com |
2024-10-22 13:54:00 |
Czytaj oryginał (ang.) |
| Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity |
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Bl |
globenewswire.com |
2024-10-21 11:30:00 |
Czytaj oryginał (ang.) |
| Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock |
NEWPORT BEACH, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a leader in medical aesthetics, today announced the commencement of an offer to exchange up to 15,000,000 shares of its currently issued and outstanding common stock, par value $0.0001 per share (the “Common Stock”) for up to 15,000,000 shares of the Company's newly issued Series B Preferred Stock (“Series B Preferred Stock”), with each share of Common Stock being exchangeable in for one share of Series B Preferred Stock. |
globenewswire.com |
2024-10-04 21:08:00 |
Czytaj oryginał (ang.) |
| REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations |
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, |
globenewswire.com |
2024-10-03 19:45:00 |
Czytaj oryginał (ang.) |
| Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations |
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, |
globenewswire.com |
2024-10-03 11:30:00 |
Czytaj oryginał (ang.) |
| Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device |
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medic |
globenewswire.com |
2024-10-02 12:30:00 |
Czytaj oryginał (ang.) |
| Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB) |
New York, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered follow-on offering (the “Offering”) of approximately $8.0 million for its client Elevai Labs Inc. (NASDAQ: ELAB) (the “Company”), a pioneering force in medical aesthetics. |
globenewswire.com |
2024-09-24 21:00:00 |
Czytaj oryginał (ang.) |
| Dow Gains Over 50 Points; Elevai Labs Shares Plummet |
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 50 points on Monday. |
benzinga.com |
2024-09-23 18:35:57 |
Czytaj oryginał (ang.) |
| Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering |
NEWPORT BEACH, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold. |
globenewswire.com |
2024-09-23 12:45:00 |
Czytaj oryginał (ang.) |
| Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications |
Case Studies Highlight Potential of Elevai Exosome Technology in Melasma Care When Used with Laser Therapy. Early Results Show Synergistic Effects of Elevai Exosomes™ and Laser Treatments for Melasma Improvement, With No Recurrence After Six Months. |
globenewswire.com |
2024-09-10 11:30:00 |
Czytaj oryginał (ang.) |